Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: Methadone and buprenorphine

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 6, 2013, Pages 675-697

  Moody, David E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Buprenorphine; Cytochrome P450; Drug interaction; Drug metabolism; Human ether a go go related gene K+ channels; Methadone; Opioid receptor agonists; Opioid replacement therapy; P glycoprotein; Prolonged QT interval; Respiratory depression; UDP glucuronosyltransferase

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; FENTANYL; GLUCURONOSYLTRANSFERASE 2B7; HYDROCODONE; HYDROMORPHONE; METHADONE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; NORBUPRENORPHINE; OXYCODONE; OXYMORPHONE; PARACETAMOL; POTASSIUM CHANNEL HERG;

DRUG FORMULATION; DRUG METABOLISM; DRUG STRUCTURE; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; MEDLINE; METABOLITE; MORTALITY; NONHUMAN; OPIATE SUBSTITUTION TREATMENT; PEER REVIEW; PHARMACODYNAMICS; PHENOTYPE; REVIEW; SYSTEMATIC REVIEW; TOXICOLOGY; UNITED STATES;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DRUG INTERACTIONS; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PAIN;

EID: 84877851541     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.783567     Document Type: Review

References (158)

1. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005;162:1432-40.
2. Dole VP, Nyswander MK, Kreek MJ. Narcotic blockade. Arch Intern Med 1966;118:304-9.
3. Deamer RL, Wilson DR, Clark DS, et al. Torsades de Pointes associated with high dose levomethadyl acetate (ORLAAM-). J Addict Dis 2001;20:7-14.
4. Resnick RB. Food and Drug Administration approval of buprenorphine- naloxone for office treatment of addiction. Ann Int Med 2003;138:360.
5. Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537-45.
6. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-80.
7. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadol acetate, buprenorphine and methadone for opioid dependence. N Engl J Med 2000;343:1290-7.
8. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012;31:207-25.
9. Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs 2012;72:217-28.
10. Soyka M, Apelt SM, Lieb M, et al. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006;26:657-60.
11. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I-evidence assessment. Pain Physician 2012;15:S1-65.
12. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2-guidance. Pain Physician 2012;15:S67-116.
13. Rosenblum A, Cruciani RA, Strain EC, et al. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. J Opioid Manag 2012;8:369-82.
14. Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther 2010;88:307-17.
15. Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: what do we know? Am J Addict 2010;19:73-88.
16. CDC. Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2012;61:493-7.
17. Johanson CE, Arfken CL, di Menza S, et al. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend 2012;120:190-5.
18. Manchikanti L, Helm S II, Fellows B, et al. Opioid epidemic in the United States. Pain Physician 2012;15:ES9-38.
19. Kuehn BM. Methadone overdose deaths rise with increased prescribing for pain. J Am Med Assoc 2012;308:749-50.
20. Litovitz TL, Klein-Schwartz W, White S, et al. 2000; Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001;19:337-95.
21. Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, et al. 2001 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002;20:391-452.
22. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003;21:353-421.
23. Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2004;22:335-404.
24. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005;23:589-666.
25. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) 2006;44:803-932.
26. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila) 2007;45:815-917.
27. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila) 2008;46:927-1057.
28. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009;47:911-1084.
29. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010;48:979-1178.
30. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011;49:910-41.
31. SAMHSA. Drug abuse warning network, 2006: national estimates of drug-related emergency department visits. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2008.
32. SAMHSA. Drug abuse warning network, 2007: national estimates of drug-related emergency department visits. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2010.
33. SAMHSA. Drug abuse warning network, 2008: national estimates of drug-related emergency department visits. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2011.
34. Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther 2011;89:443-9.
35. Middleton LS, Nuzzo PA, Loftwall MR, et al. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 2011;106:1460-73.
36. Heit HA, Gourlay DL. Buprenorphine - new tricks with an old molecule for pain management. Clin J Pain 2008;24:93-7.
37. Florian J, Garnett CE, Nallani SC, et al. A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clin Pharmacol Ther 2012;91:666-72.
38. Bruce RD, Altice FL, Gourevitch MN, et al. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006;41:563-72.
39. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010;19:4-16.
40. Sullivan HR, Due SL. Urinary metabolites of d,l-methadone in maintenance subjects. J Med Chem 1973;16:909-13.
41. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-73.
42. Moody DE, Alburges ME, Parker RJ, et al. The involvement of cytochrome P450 3A in the N-demethylation of l-a-acetylmethadol (LAAM), norLAAM and methadone. Drug Metab Dispos 1997;25:1347-53.
43. Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-12.
44. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 2003;31:742-7.
45. Prost F, Thormann W. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes-): Application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 2003;24:2577-87.
46. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004;16:36-44.
47. Kharasch ED, Hoffer C, Whittington D, et al. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69.
48. Foster DJR, Somogyi AA, Dyer KR, et al. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 2000;50:427-40.
49. Moody DE, Lin SN, Chang Y, et al. An enantiomer selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine and liver microsomes. J Anal Toxicol 2008;32:208-19.
50. Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008;108:363-74.
51. Chang Y, Fang WB, Lin SN, et al. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 2011;108:55-62.
52. Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001;298:1021-32.
53. Crettol S, Digon P, Golay KP, et al. In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R, S)-methadone, LAAM and their main metabolites. Pharmacology 2007;80:304-11.
54. Hassan HE, Myers AL, Coop A, et al. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci 2009;98:4928-40.
55. Tournier N, Chevillard L, Megarbane B, et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 2010;13:905-15.
56. Shinderman M, Maxwell S, Brawand-Amey M, et al. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend 2003;69:205-11.
57. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006;80:668-81.
58. Shiran MR, Lennard MS, Iqbal MZ, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2009;67:29-37.
59. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526.
60. Crettol S, Petrovic N, Murray M. Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des 2010;16:204-19.
61. Chen CH, Wang SC, Tsou HH, et al. Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics 2011;12:1397-406.
62. Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005;78:593-604.
63. Wang SC, Ho IK, Tsou HH, et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 2011;31:463-9.
64. Hung CC, Chiou MH, Huang BH, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 2011;12:1525-33.
65. Fonseca F, de la Torre R, Diaz L, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One 2011;6:e19527.
66. Levran O, Peles E, Hamon S, et al. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 2011.
67. Eap CB, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001;21:229-34.
68. de los Cobos JP, Sinol N, Trujols J, et al. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007;89:190-4.
69. Tian JN, Ho IK, Tsou HH, et al. UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics 2012;13:879-88.
70. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 2012;27:85-105.
71. Coller JK, Barratt DT, Dahlen K, et al. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006;80:682-90.
72. Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008;17:2219-27.
73. Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984;12:577-81.
74. Iribarne C, Picart D, Dreano Y, et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997;60:1953-64.
75. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998;26:818-21.
76. Moody DE, Slawson MH, Strain EC, et al. A liquid chromatographic- electrospray ionizationtandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 2002;306:31-9.
77. Picard N, Cresteil T, Djebli N, et al. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 2005;33:689-95.
78. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos 2006;34:440-8.
79. Moody DE, Chang Y, Huang W, et al. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin Pharmacol Toxicol 2009;105:211-15.
80. Moody DE, Fang WB, Lin SN, et al. Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes. Drug Metab Dispos 2009;37:2323-9.
81. Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 2009;3:101-7.
82. Rouguieg K, Picard N, Sauvage FL, et al. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 2010;38:40-5.
83. Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionizationtandem mass spectrometry. Ther Drug Monit 2006;28:245-51.
84. McMillin GA, Davis R, Carlisle H, et al. Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2012;36:81-7.
85. Brown SM, Campbell SD, Crafford A, et al. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J Pharmacol Exp Ther 2012;343:53-61.
86. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010;112:226-38.
87. Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 2005;26:119-24.
88. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 2011;115:1363-81.
89. Traynor J. mu-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 2012;121:173-80.
90. Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding properties of methadone stereoisomers and morphine. Life Sci 1995;56:45-50.
91. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688-95.
92. Brown SM, Holtzman M, Kim T, et al. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 2011;115:1251-60.
93. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011-14.
94. Horng JS, Smits SE, Wong DT. The binding of optical isomers of methadone, a-acetylmethadol and their N-demethylated derivatives to the opiate receptors of rat brain. Res Commun Chem Pathol Pharmacol 1976;14:621-9.
95. Lotsch J, Skarke C, Wieting J, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006;79:72-89.
96. Selley DE, Liu Q, Childers SR. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 1998;285:496-505.
97. McPherson J, Rivero G, Baptist M, et al. mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 2010;78:756-66.
98. Scott CC, Robbins EB, Chen KK. Pharmacological comparison of the optical isomers of methadon. J Pharmacol Exp Ther 1948;92:282-6.
99. Pohland A, Boaz HE, Sullivan HR. Synthesis and identification of metabolites resulting from the biotransformation of dl-methadone in man and in the rat. J Med Chem 1971;14:194-7.
100. Sullivan HR, Smitz SE, Due SL, et al. Metabolism of d-methadone: isolation and identification of analgesically active metabolites. Life Sci 1972;11:1093-104.
101. Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphineand norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995;272:505-10.
102. Holm KM, Linnet K. Chiral analysis of methadone and its main metabolite, EDDP, in postmortem brain and blood by automated SPE and liquid chromatography-mass spectrometry. J Anal Toxicol 2012;36:487-96.
103. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998;22:430-4.
104. Liu SJ, Roerig DL, Wang RI. Brain and plasma levels of methadone and their relationships to analgesic activity of methadone in rats. Drug Metab Dispos 1983;11:335-8.
105. Garrido MJ, Valle M, Calvo R, et al. Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J Pharmacol Exp Ther 1999;288:179-87.
106. Bauer B, Yang XD, Hartz AMS, et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 2006;70:1212-19.
107. Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 2007;35:660-6.
108. Foster DJ, Upton RN, Somogyi AA, et al. The acute disposition of (R)- and (s)-methadone in brain and lung of sheep. J Pharmacokinet Pharmacodyn 2005;32:547-70.
109. Jensen ML, Foster D, Upton R, et al. Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica 2007;37:441-57.
110. Rodriguez M, Ortega I, Soengas I, et al. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J Pharm Pharmacol 2004;56:367-74.
111. Wang JS, Ruan Y, Taylor RM, et al. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacolgy 2004;173:132-8.
112. Tournier N, Decleves X, Saubamea B, et al. Opioid transport by ATP-binding cassette (ABC) transporters at the blood-brain barrier: implications for neuropsychopharmacology. Curr Pharm Des 2011;17:2829-42.
113. Bouer R, Barthe L, Philibert C, et al. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol 1999;13:494-500.
114. Nanovskaya T, Nekhayeva I, Karunaratne N, et al. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 2005;69:1869-78.
115. Nekhayeva IA, Nanovskaya TN, Hankins GDV, et al. Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alphaacetylmethadol, and paclitaxel. Am J Perinatol 2006;23:423-30.
116. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000;92:1392-9.
117. Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 2004;67:269-76.
118. Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004;57:600-10.
119. Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go related gene K+ currents. J Pharmacol Exp Ther 2002;303:688-94.
120. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167:2469-75.
121. Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007;81:719-28.
122. Lin C, Somberg T, Molnar J, et al. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 2009;113:59-65.
123. Ansermot N, Albayrak O, Schlapfer J, et al. Substitution of (R,S)-methadone by (R)-methadone - Impact on QTc interval. Ar1. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005;162:1432-40.
124. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010;376:367-87.
125. Baker J, Rainey PM, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine and tenofovir. Am J Addict 2010;19:17-29.
126. McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict 2006;15:23-34.
127. Gruber VA, Rainey PM, Moody DE, et al. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin Infect Dis 2012;54:414-23.
128. McCance-Katz EF, Moody DE, Prathikanti S, et al. Rifampin, but nor rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend 2011;118:326-34.
129. Kharasch ED, Bedynek PS, Park S, et al. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther 2008;84:497-505.
130. Kharasch ED, Walker A, Whittington D, et al. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009;101:158-68.
131. Kirby BJ, Collier AC, Kharasch ED, et al. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos 2011;39:2329-37.
132. Anggard E, Gunne L-M, Holmstrand J, et al. Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 1975;17:258-66.
133. Verebly K, Volavka J, Mule S, et al. Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975;18:180-90.
134. Buchard A, Linnet K, Johansen SS, et al. Postmortem blood concentrations of Rand S-enantiomers of methadone and EDDP in drug users: influence of co-medication and P-glycoprotein genotype. J Forensic Sci 2010;55:457-63.
135. Barrett DH, Luk AJ, Parrish RG, et al. An investigation of Medical Examiner cases in which methadone was detected, Harris county, Texas, 1987-1992. J Forensic Sci 1996;41:442-8.
136. Jones AW, Holmgren A, Ahlner J. Blood methadone concentrations in living and deceased persons: variations over time, subject deographics, and relevance of coingested drugs. J Anal Toxicol 2012;36:12-18.
137. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001;121:65-9.
138. Lai SH, Yao YJ, Lo DST. A survey of buprenorphine related deaths in Singapore. Forensic Sci Int 2006;162:80-6.
139. Pirnay S, Borron SW, Giudicelli CP, et al. A critical review of the causes of death among postmortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004;99:978-88.
140. Moody DE. Drug interactions with benzodiazepines: Epidemiologic correlates with other CNS depressants and in vitro correlates with inhibitors and inducers of cytochrome P450 3A4. In: Mozayani A, Raymon LP, editors. Handbook of drug interactions a clinical and forensic guide. 2nd edition. Humana Press, New York, NY; 2012. p. 25-116.
141. Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict 2010;19:59-72.
142. Chang Y, Moody DE. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur J Clin Pharmacol 2005;60:875-81.
143. Pirnay S, Megarbane B, Decleves X, et al. Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats. Toxicol Sci 2008;106:64-73.
144. Jung BF, Reidenberg MM. Interpretation of opioid levels: comparison of levels during chronic pain therapy to levels from forensic autopsies. Clin Pharmacol Ther 2005;77:324-34.
145. Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667-715.
146. Wong SH, Wagner MA, Jentzen JM, et al. Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity. J Forensic Sci 2003;48:1406-15.
147. Bunten H, Liang WJ, Seneviratne C, et al. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010;88:383-9.
148. Bunten H, Liang WJ, Pounder DJ, et al. Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations. J Anal Toxicol 2011;35:431-7.
149. Kharasch ED, Hoffer C, Whittington D, et al. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport. Anesthesiology 2009;110:660-72.
150. Rubenstein RB, Kreek MJ, Mbawa N, et al. Human spinal fluid methadone levels. Drug Alcohol Depend 1978;3:103-6.
151. Henriksen G, Willoch F. Imaging of opioid receptors in the central nervous system. Brain 2008;131:1171-96.
152. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28:2000-9.
153. Greenwald M, Johanson CE, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiat 2007;61:101-10.
154. Melichar JK, Hume SP, Williams TM, et al. Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther 2005;312:309-15.
155. Kling MA, Carson RE, Borg L, et al. Opioid receptor imaging with positron emission tomography and [(18)F] cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000;295:1070-6.
156. Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars) 2011;71:113-28.
157. Benedek IH, Jobes J, Xiang Q, et al. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther 2011;5:455-63.
158. Neff JA, Moody DE. Differential N-demethylation of l-a-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4. Biochem Biophys Res Commun 2001;284:751-6.